GEN Exclusives

More »

GEN News Highlights

More »
Jun 11, 2009

Lohocla to Use Biosystems International’s Platform for Alcoholic Liver Disease Biomarker Discovery

  • Lohocla Research established a licensing agreement for the use of Biosystems International’s (BSI) mAb proteomics platform. Lohocla will utilize the technology for the discovery of alcoholic liver disease biomarkers in the blood.

    BSI reports that it uses a hypothesis-free process to perform mAb-based comparative and quasi-global plasma proteome profiling. This allows the detection of potential biomarker candidates with no preconceived bias, the firm states. As a result, the BSI discovery process claims to provide tools for quantitative biomarker assays in clinical trials, which is something the company says current proteomics-based approaches do not deliver.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using Pet Dogs with Cancer in Preclinical Trials

Do you agree that pet dogs with cancer should be used in early cancer drug trials?

More »